Mark Gergen

Mark J.
Gergen is an Independent Director at Aristea Therapeutics, Inc. He previously served as the Executive Chairman at Poseida Therapeutics, Inc. from 2024 to 2025.
Mark also held positions as a Director at Aperio Technologies, Inc., Chief Financial & Development Officer at Advanced Tissue Sciences, Inc. from 1999 to 2003, and Senior Vice President-Corporate Development at Amylin Pharmaceuticals, Inc. from 2005 to 2012.
He was also a Principal at Jostens, Inc. and Medtronic, Inc. Mark served as the Chief Operating Officer & Senior Vice President at Halozyme Therapeutics, Inc. from 2016 to 2017, and as the Executive Vice President at CardioNet LLC from 2003 to 2005.
He was also a Principal at Premier Healthcare Solutions, Inc. and served as the Chief Operating Officer, Secretary & Executive VP at Mirati Therapeutics, Inc. in 2016.
Mr. Gergen obtained his undergraduate degree from Minot State University and his graduate degree from The University of Minnesota Law School.